INmune Bio Inc. (NASDAQ: INMB) has announced the upcoming release of a video detailing additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor. This video will be available on the company's YouTube Channel following the conclusion of the Alzheimer's Association International Conference $(AAIC)$ in Toronto, Canada. The video presentation will provide a comprehensive overview of the clinical insights shared during AAIC, focusing on the evaluation of XPro™ within the MINDFuL study design and its significance for early-stage Alzheimer's disease therapies. The presentation at AAIC is scheduled for July 29, 2025, from 2:00 to 3:30 PM ET, with the video being made available at 4 PM ET on July 31, 2025. The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study that has demonstrated consistent benefits in slowing cognitive decline in a subpopulation of patients with early-stage Alzheimer's disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.